Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

• Sponsor: Indiana University (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02885324
• Collaborator: (none)
• Enrollment: 4
• Location: 1
• Arm: 1
• Actual Duration (Months): 39.3
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival

Condition or Disease	Intervention/Treatment	Phase
Glioblastoma Multiforme; Anaplastic Astrocytoma; Malignant Brain Tumor; High Grade Glioma	Drug: Cabozantinib	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 4 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
• Actual Study Start Date: May 18, 2017
• Actual Primary Completion Date: Aug 25, 2020
• Actual Study Completion Date: Aug 25, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cabozantinib Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.	Drug: Cabozantinib; Subjects will receive Cabozantinib; Other Names: XL 184 Cabometyx

Outcome Measures

Primary Outcome Measures

1. Disease Response [6 months]

   Response criteria are assessed based on the product of the longest diameter and its longest perpendicular diameter. Complete response (CR): Disappearance of all target lesions Partial response (PR): ≥50% decrease in the sum of the products of the two perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements Stable disease (SD): Neither sufficient decrease in the sum of the products of the two perpendicular diameters of all target lesions to qualify for PR, nor sufficient increase in a single target lesion to qualify for PD. Progressive Disease (PD): The appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 2 Years to 21 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria

1. Age: Patients must be ≥2 years and ≤21 years of age

2. Diagnosis: Patients with relapsed or refractory central nervous system tumors. Patients must have had histological verification of malignancy at original diagnosis or relapse. Metastatic disease to the spine or primary tumors in the spine are eligible. Patients may be in first, second, or third relapse. Subjects with intrinsic brain stem gliomas may be eligible with or without histological confirmation. Please contact study chair prior to enrollment.

3. Disease Status: Patients must have measurable disease. Linear enhancement of leptomeningeal without measurable mass is excluded.

4. Therapeutic Options: Patient's current disease state must be one for which there is no accepted standard therapy, no known curative therapy or therapy proven to prolong survival with an acceptable quality of life. For patients in whom surgery is feasible, maximal surgical resection must have occurred.

5. Performance Level: Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix 1). Note: Neurologic deficits in patients must have been relatively stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

6. Subjects must have a reasonable life expectancy of at least 2 months.

7. Prior Therapy

1. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy i. Cytotoxic chemotherapy (including investigational agents) or biologic agents (eg. Cytokines or antibodies): At least 3 weeks after the last dose.

1. Nitrosoureas/mitomycin C: At least 6 weeks from the last dose. iii. XRT: At least 14 days after local palliative XRT (small port); At least 150 days must have elapsed if prior TBI, craniospinal XRT or if ≥ 50% radiation of pelvis; At least 42 days must have elapsed if other substantial BM radiation. e.g. Stem cell Infusion without TBI: No evidence of active graft vs. host disease and at least 56 days must have elapsed after transplant or stem cell infusion.

1. Organ Function Requirements:

1. Adequate bone marrow function defined as: absolute neutrophil count (ANC ≥1000/mm3)
2. Platelet count ≥ 100,000/ mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) ii. Patients with bone marrow metastatic disease will not be eligible. b. Adequate renal function defined as:
3. Creatinine clearance or radioisotope GFR ≥ 70mL/min/1.73 m² or a serum creatinine based on age/gender as follows:

Age Maximum Serum Creatinine (mg/dL) Male Female 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

≥ 16 years 1.7 1.4 The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.

1. Urine protein: ≤ 30 mg/dL in urinalysis or ≤ 1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 hour urine sample.

1. Adequate Liver Function Defined as:

2. Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age ii. SGPT (ALT) ≤ 110 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.

1. Serum albumin ≥ 2.8 g/dL. d. Adequate coagulation status defined as: PT and INR ≤ 1.5x ULN e. Adequate pancreatic function defined as: Serum amylase and lipase ≤ 1.5 x ULN f. Adequate blood pressure control defined as: A blood pressure (BP) ≤ the 95th percentile for age, height and gender (Appendix II) despite optimal antihypertensive treatment within 7 days of the first dose of the study treatment. Please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP.

1. Central nervous system function defined as: Patients with seizure disorder may be enrolled if receiving non-enzyme inducing anticonvulsants and well controlled. See Appendix III for a list of recommended non-enzyme inducing anticonvulsants.

2. Adequate cardiac function defined as: i. No history of congenital QTc syndrome, NYHA Class III or IV congestive heart failure (CHF) ii. No clinical significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment iii. QTc

≤ 480 msec. Note: One ECG must be performed for eligibility determination. If the QTc is > 480 msec, two additional ECGs must be performed and the average of the three ECGs will be used to determine eligibility. Patients with Grade 1 prolonged QTc (450-480 msec) at the time of study enrollment should have correctable causes of prolonged QTc addressed if possible (i.e. electrolytes, medications). See Appendix IV for a list of drugs that prolong QTc.

1. Informed consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate will be obtained according to institutional guidelines.

2. Archival tumor tissue slides must be sent or available, except for patients with intrinsic pontine glioma meeting the remainder of the inclusion criteria.

Exclusion Criteria

1. Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogentic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control- during protocol therapy and for at least 4 months after the last dose of cabozantinib. Abstinence is an acceptable method of birth control.

2. Concomitant Medications:

3. Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.

4. Investigational drugs: Patients who are currently receiving another investigational drug are not eligible.

5. Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible.

6. CYP3A4 active agents: Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort. A list of other known CYP3A4 inducers and inhibitors that should be discontinued prior to initiation of protocol therapy and should be avoided during study therapy if reasonable alternatives exist is included in Appendix V.

7. Patients who are receiving systemic therapeutic treatment anticoagulation are not eligible. Patients receiving prophylactic systemic anticoagulation will be allowed with heparin or LMWH as long as eligibility PT/INR requirements are met. Concomitant anticoagulation with oral anticoagulations (e.g. warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg. Clopidogrel) are not allowed.

8. Enzyme-inducing anticonvulsants: Patients must not have received enzyme-inducing anticonvulsants within 14 days prior to enrollment (See Appendix III for a list of unacceptable enzyme inducing anticonvulsants).

9. QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible (See Appendix IV for a list of agents).

10. Patients must be able to swallow intact tablets. Patients who cannot swallow intact tablets are not eligible.

11. Patients with active bleeding are not eligible. Specifically, no clinically significant GI bleeding, GI perforation, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment.

12. Patients with evidence of an acute intracranial or intratumoral hemorrhage on CT or MRI are not eligible (patients with evidence of resolving hemorrhage will be eligible).

13. Major surgery within 28 days of enrollment. Complete wound healing from major or minor surgery must have occurred prior to enrollment. Minor surgery (including uncomplicated tooth extractions) within 7 days of enrollment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible;

14. Concurrent uncontrolled hypertension defined as sustained blood pressure>95% for age, height and gender (systolic or diastolic) despite optimal antihypertensive treatment within 7 days of the first dose of study treatment.

15. Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of this oral agent are not eligible.

16. Infection: Patients who have an uncontrolled infection are not eligible.

17. Patients who have received a prior solid organ transplantation are not eligible.

18. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.

19. Subjects who have received cabozantinib or have an allergy to cabozantinib are excluded. Subjects who have previously received tyrosine kinase inhibitors are allowed.

20. Subjects who have not received radiation therapy as part of their prior treatment are excluded.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Riley Hospital for Children at IU Health	Indianapolis	Indiana	United States	46202

Sponsors and Collaborators

• Indiana University

Investigators

• Principal Investigator: Scott Coven, DO, Indiana University School of Medicine

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Mar 5, 2021
• Informed Consent Form - Mar 5, 2021

More Information

Publications

None provided.

• Responsible Party: Scott Coven, Assistant Professor, Indiana University
• ClinicalTrials.gov Identifier: NCT02885324
• Other Study ID Numbers: IUSCC-0601
• First Posted: Aug 31, 2016
• Last Update Posted: Aug 15, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Scott Coven, Assistant Professor, Indiana University: High Grade Glioma; Cabozantinib; GBM; Children; AA
• Additional relevant MeSH terms: Glioblastoma; Glioma; Brain Neoplasms; Astrocytoma; Nervous System Neoplasms; Central Nervous System Neoplasms

Study Results

Participant Flow

Arm/Group Title	Cabozantinib
Arm/Group Description	Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study. Cabozantinib: Subjects will receive Cabozantinib
Period Title: Overall Study
STARTED	4
COMPLETED	4
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Cabozantinib
Arm/Group Description	Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study. Cabozantinib: Subjects will receive Cabozantinib
Overall Participants	4
Age (Count of Participants)
<=18 years	4 100%
Between 18 and 65 years	0 0%
>=65 years	0 0%
Sex: Female, Male (Count of Participants)
Female	1 25%
Male	3 75%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	1 25%
White	3 75%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	4 100%

Outcome Measures

1. Primary Outcome

Title	Disease Response
Description	Response criteria are assessed based on the product of the longest diameter and its longest perpendicular diameter. Complete response (CR): Disappearance of all target lesions Partial response (PR): ≥50% decrease in the sum of the products of the two perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements Stable disease (SD): Neither sufficient decrease in the sum of the products of the two perpendicular diameters of all target lesions to qualify for PR, nor sufficient increase in a single target lesion to qualify for PD. Progressive Disease (PD): The appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time Frame	6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Cabozantinib
Arm/Group Description	Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study. Cabozantinib: Subjects will receive Cabozantinib
Measure Participants	4
Count of Participants [Participants]	4 100%

Adverse Events

Time Frame	4 months
Arm/Group Title	Cabozantinib
Arm/Group Description	Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study. Cabozantinib: Subjects will receive Cabozantinib
All Cause Mortality
	Cabozantinib
	Affected / at Risk (%)	# Events
Total	4/4 (100%)
Serious Adverse Events
	Cabozantinib
	Affected / at Risk (%)	# Events
Total	0/4 (0%)
Other (Not Including Serious) Adverse Events
	Cabozantinib
	Affected / at Risk (%)	# Events
Total	4/4 (100%)
Blood and lymphatic system disorders
Epistaxis	1/4 (25%)
Hemoglobin increased	1/4 (25%)
Cardiac disorders
Hypertension	1/4 (25%)
Endocrine disorders
Hypothyroidism	3/4 (75%)
Eye disorders
Blurred vision	1/4 (25%)
Dry eye	1/4 (25%)
diplopia	1/4 (25%)
right visual field deficit	1/4 (25%)
Gastrointestinal disorders
Abdominal pain	2/4 (50%)
Diarrhea	2/4 (50%)
Dyspepsia	1/4 (25%)
Nausea	1/4 (25%)
Stomach pain	1/4 (25%)
Vomiting	1/4 (25%)
General disorders
Dysgeusia	1/4 (25%)
Fatigue	3/4 (75%)
Gait disturbance	2/4 (50%)
Headache	2/4 (50%)
Hemorrhoids	1/4 (25%)
Hypoxia	1/4 (25%)
Intracranial hemorrhage	1/4 (25%)
Lipase increased	1/4 (25%)
Serum amylase increased	1/4 (25%)
Somnolence	1/4 (25%)
Voice alteration	1/4 (25%)
Hepatobiliary disorders
Alanine aminotransferase increased	1/4 (25%)
Aspartate aminotransferase increased	2/4 (50%)
Blood bilirubin increased	1/4 (25%)
jaundice	1/4 (25%)
Injury, poisoning and procedural complications
stubbed toe	1/4 (25%)
Pain in extremity	2/4 (50%)
Metabolism and nutrition disorders
Anorexia	2/4 (50%)
Weight loss	1/4 (25%)
Musculoskeletal and connective tissue disorders
Arthralgia	1/4 (25%)
Generalized muscle weakness	1/4 (25%)
Laryngeal inflammation	1/4 (25%)
Myalgia	2/4 (50%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Progressive Disease	1/4 (25%)
Nervous system disorders
unable to coordinate movements	1/4 (25%)
Seizure	1/4 (25%)
Psychiatric disorders
Agitation	1/4 (25%)
Anxiety	1/4 (25%)
Confusion	1/4 (25%)
Depressed level of consciousness	1/4 (25%)
Dysarthria	1/4 (25%)
Dysphasia	1/4 (25%)
Memory impairment	1/4 (25%)
Renal and urinary disorders
Proteinuria	2/4 (50%)
Urinary retention	1/4 (25%)
Respiratory, thoracic and mediastinal disorders
Cough	1/4 (25%)
Nasal congestion	1/4 (25%)
Respiratory failure	1/4 (25%)
respiratory secretions	1/4 (25%)
subject hospitalized in acute respiratory failure	1/4 (25%)
Skin and subcutaneous tissue disorders
Dry skin	1/4 (25%)
Palmar-plantar erythrodysethesia syndrome	1/4 (25%)
Rash acneiform	2/4 (50%)
hair color change	2/4 (50%)
Skin infection	1/4 (25%)

Limitations/Caveats

Early termination leading to small numbers of subjects analyzed.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.